Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pablo Barreiro

Showing results (211-220 of 220) with videos related to

Pageof 22
Sort By:
You have reached the last page of results.This site can display upto 220 results.
Travel Medicine and Infectious Disease|December 6, 2019
Characteristics of Zika virus infection among international travelers: A prospective study from a Spanish referral unitClara Crespillo-Andújar, Marta Díaz-Menéndez, Elena Trigo, et al.
Viruses|February 28, 2023
Temporal Series Analysis of Population Cycle Threshold Counts as a Predictor of Surge in Cases and Hospitalizations during the SARS-CoV-2 PandemicFernando Cava, Jesús San Román, Pablo Barreiro, et al.
The Journal of Infectious Diseases|July 19, 2012
Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trialPablo Labarga, Pablo Barreiro, Alfredo da Silva, et al.
AIDS Research and Human Retroviruses|August 30, 2007
Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trialMarina Núñez, Celia Miralles, Miguel Angel Berdún, et al.
Vaccines|March 26, 2022
Humoral and Cellular Response after mRNA Vaccination in Nursing Homes: Influence of Age and of History of COVID-19Jesús San Román, Francisco Javier Candel, Juan Carlos Sanz, et al.
AIDS (London, England)|July 13, 2017
Human T-lymphotropic virus type 1 infection and disease in SpainCarmen de Mendoza, Estrella Caballero, Antonio Aguilera, et al.
Antiviral Therapy|August 3, 2007
Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirinVincent Soriano, Celia Miralles, Miguel Angel Berdún, et al.
The Journal of Antimicrobial Chemotherapy|October 16, 2008
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backboneJosé A Mira, Luis F López-Cortés, Pablo Barreiro, et al.
Viruses|July 29, 2023
Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2Francisco Javier Candel, Pablo Barreiro, Miguel Salavert, et al.
Open Forum Infectious Diseases|September 22, 2020
Development of a Standardized Data Collection Tool for Evaluation and Management of Coronavirus Disease 2019Stephen R Morris, Yoichiro Natori, Douglas Salguero, et al.
Pageof 22

Showing results (211-220 of 220) with videos related to

Sort By:
Pageof 22
You have reached the last page of results.This site can display upto 220 results.
Travel Medicine and Infectious Disease|December 6, 2019
Characteristics of Zika virus infection among international travelers: A prospective study from a Spanish referral unitClara Crespillo-Andújar, Marta Díaz-Menéndez, Elena Trigo, et al.
Viruses|February 28, 2023
Temporal Series Analysis of Population Cycle Threshold Counts as a Predictor of Surge in Cases and Hospitalizations during the SARS-CoV-2 PandemicFernando Cava, Jesús San Román, Pablo Barreiro, et al.
The Journal of Infectious Diseases|July 19, 2012
Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trialPablo Labarga, Pablo Barreiro, Alfredo da Silva, et al.
AIDS Research and Human Retroviruses|August 30, 2007
Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trialMarina Núñez, Celia Miralles, Miguel Angel Berdún, et al.
Vaccines|March 26, 2022
Humoral and Cellular Response after mRNA Vaccination in Nursing Homes: Influence of Age and of History of COVID-19Jesús San Román, Francisco Javier Candel, Juan Carlos Sanz, et al.
AIDS (London, England)|July 13, 2017
Human T-lymphotropic virus type 1 infection and disease in SpainCarmen de Mendoza, Estrella Caballero, Antonio Aguilera, et al.
Antiviral Therapy|August 3, 2007
Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirinVincent Soriano, Celia Miralles, Miguel Angel Berdún, et al.
The Journal of Antimicrobial Chemotherapy|October 16, 2008
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backboneJosé A Mira, Luis F López-Cortés, Pablo Barreiro, et al.
Viruses|July 29, 2023
Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2Francisco Javier Candel, Pablo Barreiro, Miguel Salavert, et al.
Open Forum Infectious Diseases|September 22, 2020
Development of a Standardized Data Collection Tool for Evaluation and Management of Coronavirus Disease 2019Stephen R Morris, Yoichiro Natori, Douglas Salguero, et al.
Pageof 22